April 21, 2025 01:04 PM EDT

Alvogen unit appeals court loss shielding Bausch Health's IBS drug from generics

Alexis Kramer

Deputy Editor

Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch Health’s Xifaxan to market, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Alvogen unit appeals court loss shielding Bausch Health's IBS drug from generics

Alexis Kramer

Deputy Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Alvo­gen unit ap­peals court loss shield­ing Bausch Health's IBS drug from gener­ics

Deputy Editor

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Alvogen unit appeals court loss shielding Bausch Health's IBS drug from generics